David Dai

Stock Analyst at UBS

(0.53)
# 3,973
Out of 4,905 analysts
26
Total ratings
22.73%
Success rate
-23.76%
Average return

Stocks Rated by David Dai

Syndax Pharmaceuticals
Jul 15, 2025
Maintains: Buy
Price Target: $37$35
Current: $9.46
Upside: +269.98%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30$26
Current: $11.21
Upside: +131.94%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $26.20
Upside: +14.50%
Blueprint Medicines
Jun 5, 2025
Maintains: Neutral
Price Target: $88$129
Current: $129.46
Upside: -0.36%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17$2
Current: $2.23
Upside: -10.31%
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30$24
Current: $7.53
Upside: +218.73%
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $83.31
Upside: +20.04%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27$14
Current: $6.36
Upside: +120.13%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $36.32
Upside: -33.92%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $4.20
Upside: +376.19%
Initiates: Buy
Price Target: $72
Current: $63.26
Upside: +13.82%
Initiates: Buy
Price Target: $69
Current: $26.40
Upside: +161.36%
Initiates: Buy
Price Target: $50
Current: $21.59
Upside: +131.59%
Initiates: Buy
Price Target: $60
Current: $26.75
Upside: +124.30%
Initiates: Outperform
Price Target: $28
Current: $0.76
Upside: +3,586.64%
Initiates: Outperform
Price Target: $40
Current: $24.42
Upside: +63.80%
Initiates: Outperform
Price Target: $40
Current: $1.48
Upside: +2,602.70%
Initiates: Outperform
Price Target: $50
Current: $1.91
Upside: +2,517.80%
Upgrades: Outperform
Price Target: $41$52
Current: $33.92
Upside: +53.30%